课题基金 / 基金详情

PREOPERATIVE BEXAROTENE TREATMENT FOR CUSHING'S DISEASE

PREOPERATIVE BEXAROTENE TREATMENT FOR CUSHING'S DISEASE
库欣病术前贝沙罗汀治疗
批准号:
8167193
负责人:
MARY L VANCE
金额:
$2.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2013-02-28

项目摘要

项目成果

MARY L VANCE的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 背景:库欣病是一种由促肾上腺皮质激素(ACTH)产生的垂体肿瘤引起的糖皮质激素过多的疾病,占所有垂体肿瘤的10-15%。大多数促肾上腺皮质细胞肿瘤在诊断时是微腺瘤,准确的手术和组织学鉴定这些肿瘤可能是具有挑战性的。促肾上腺皮质激素是通过前体阿片黑素皮质素(POMC)在垂体前叶的促肾上腺皮质激素细胞中产生的。在生理和病理条件下,POMC的启动子都受多种转录因子的调控,其中包括AP-1和Nurr77。维甲酸已被证明通过破坏Nurr77转录活性来抑制促肾上腺皮质激素肿瘤细胞培养中POMC启动子的激活。鸡卵清蛋白上游启动子转录因子I(COUP-TFI)是一种孤儿核受体,其表达可拮抗维甲酸信号转导,已有报道存在于正常皮质细胞中,但在组织培养研究中缺乏腺瘤细胞。通过对34例人促肾上腺皮质细胞肿瘤的回顾性分析,我们发现,在术前MRI不可见或小于5毫米的微腺瘤中,100%的肿瘤始终缺乏Coup-TFI。总体而言,所有研究的肿瘤中有85%显示没有COUP-TFI。基于大鼠和人皮质细胞肿瘤的体外数据,缺乏COUP-TFI的细胞容易通过Nurr77介导的维甲酸诱导的细胞死亡,这种作用被COUP-TFI基因转染逆转。2006年,Castillo et al.公布了一项为期六个月的试验结果,该试验将44只患有库欣病的狗随机分为RXR激动剂(9-顺式维甲酸)或酮康唑。RXR激动剂治疗在所有终点都优于酮康唑,导致100%完成研究的受试者ACTH和皮质醇水平正常化,并改善了发病率和死亡率。所有接受RXR激动剂治疗的狗在治疗后6到12个月的时间里一直处于缓解状态。 假设和目的:我们假设COUP-TFI在人类微腺瘤的正常和腺瘤皮质激素细胞中的差异表达确定了一个对维甲酸敏感的肿瘤群体,该肿瘤群体容易受到维甲酸诱导的ACTH抑制和细胞凋亡的影响。这项先导性研究的目的是确定贝克沙罗汀短期治疗库欣病患者的安全性和耐受性,并研究在接受经蝶窦手术前应用贝沙罗汀5天疗程对这些患者的临床、生化和细胞影响。主要的生化结果指标将是昼夜血浆ACTH和皮质醇,以及连续24小时尿游离皮质醇水平。 方法:这项先导性研究(n=6名受试者)将在我们的综合临床研究中心住院5天,然后进行预定的经蝶手术。在为期五天的研究中,每个人都将服用RXR激动剂贝沙罗汀,剂量为FDA批准的300 mg/m2/天。将在每24小时内定期监测急性肾上腺功能不全的临床症状和体征。将进行ACTH和皮质醇的基线和每日两次生化分析。皮质醇的24小时尿液收集将在治疗前和治疗的最后24小时内进行。实验室安全性分析将包括监测肝脏和肾脏功能的一系列综合代谢面板,监测中性粒细胞减少症的完整血细胞计数,以及监测中枢性甲状腺功能减退的甲状腺功能研究,这种甲减可能随着治疗而发展。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: Cushing's disease refers to a condition of glucocorticoid exceess caused by an adrenocorticotropic hormone (ACTH) producing pituitary tumor, which account for 10-15% of all pituitary tumors. The majority of corticotroph tumors are microadenomas at the time of diagnosis, and accurate surgical and histologic identification of these tumors can be challenging. ACTH is produced in corticotroph cells within the anterior pituitary via the precursor pro-opiomelanocortin (POMC). In both physiologic and pathologic conditions the promoter for POMC is regulated by multiple transcription factors which include AP-1 and Nurr77. Retinoic acid has been shown to inhibit activation of the POMC promoter in corticotroph tumor cell culture via disruption of Nurr77 transcriptional activity. The expression of the orphan nuclear receptor termed chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) antagonizes retinoic acid signaling, and has been reported to be present in normal corticotroph cells, but lacking in adenomatous corticotroph cells in tissue culture studies. Through the retrospective analysis of 34 human corticotroph tumors we have demonstrated a consistent lack of COUP-TFI in 100% of the microadenomas that were not visible, or measured less than 5 millimeters by preoperative MRI. In total, 85% of all tumors studied showed absence of COUP-TFI. Based on in vitro data from rat and human corticotroph tumors, cells lacking COUP-TFI are vulnerable to retinoid-induced cell death via Nurr77-mediated apoptosis, an effect that is reversed by COUP-TFI gene transfection. In 2006, Castillo et al. published the results of a six-month trial which randomized 44 dogs with Cushing's disease to an RXR agonist (9-cis retinoic acid), or to ketoconazole. RXR agonist therapy outperformed ketoconazole for all endpoints, resulting in normalization of ACTH and cortisol levels in 100% of subjects that completed the study, and improved morbidity and mortality. All of the dogs treated with the RXR agonist remained in remission for the duration of the 6 to 12 month post-treatment followup. Hypothesis and Objectives: We hypothesize that the differential expression of COUP-TFI in normal vs. adenomatous corticotroph cells in human microadenomas identifies a retinoid-sensitive tumor population which is vulnerable to retinoid-induced ACTH-suppression and apoptosis. The objective of this pilot study is to establish the safety and tolerability of short-term therapy with bexarotene in patients with Cushing's disease, and study the clinical, biochemical, and cellular effects of a preoperative five-day course of bexarotene in these patients before undergoing transsphenoidal surgery. The primary biochemical outcome measures will be diurnal plasma ACTH and cortisol, and serial 24-hour urine free cortisol levels. Methods: This pilot study (n = 6 subjects) will involve inpatient admission to our General Clinical Research Center for 5 days prior to scheduled transsphenoidal surgery. During the five days of the study each individual will receive the RXR-agonist bexarotene at the FDA approved dose of 300 mg/m2/day. Clinical signs and symptoms of acute adrenal insufficiency will be monitored routinely throughout each 24-hour period. Baseline and twice-daily biochemical analysis for ACTH and cortisol will be performed. 24-hour urine collection for cortisol will be obtained pre-treatment and in the last 24-hours of treatment. Laboratory safety analysis will include serial comprehensive metabolic panels to monitor liver and kidney function, complete blood count to monitor for neutropenia, as well as thyroid function studies to monitor for central hypothyroidism which can develop with therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DI
  • 批准号:
    8167151
  • 项目类别:
  • 资助金额:
    $0.8万
  • 财政年份:
    2010
  • 负责人:
    MARY L VANCE
  • 依托单位:
CLINICAL TRIAL: EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DI
  • 批准号:
    7951463
  • 项目类别:
  • 资助金额:
    $1.85万
  • 财政年份:
    2009
  • 负责人:
    MARY L VANCE
  • 依托单位:
CLINICAL TRIAL: EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DI
  • 批准号:
    7718544
  • 项目类别:
  • 资助金额:
    $4.65万
  • 财政年份:
    2008
  • 负责人:
    MARY L VANCE
  • 依托单位:
EFFECT OF GROWTH HORMONE TREATMENT ON RECOVERY FROM CUSHING'S DISEASE
  • 批准号:
    7606689
  • 项目类别:
  • 资助金额:
    $6.06万
  • 财政年份:
    2007
  • 负责人:
    MARY L VANCE
  • 依托单位:
海外基金